Kronos Bio, Inc. (NASDAQ:KRON - Get Free Report) shares dropped 1% during mid-day trading on Monday . The company traded as low as $0.91 and last traded at $0.95. Approximately 238,983 shares changed hands during trading, an increase of 15% from the average daily volume of 207,575 shares. The stock had previously closed at $0.96.
Analyst Ratings Changes
A number of research firms have recently weighed in on KRON. TD Cowen lowered shares of Kronos Bio from a "buy" rating to a "hold" rating in a research report on Thursday, November 14th. Piper Sandler lowered shares of Kronos Bio from an "overweight" rating to a "neutral" rating and cut their price objective for the company from $6.00 to $1.00 in a research report on Thursday, November 14th.
View Our Latest Stock Report on Kronos Bio
Kronos Bio Stock Down 1.0 %
The firm's 50 day simple moving average is $0.99 and its 200-day simple moving average is $0.97. The company has a market capitalization of $57.32 million, a PE ratio of -0.66 and a beta of 1.79.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the stock. GTS Securities LLC acquired a new stake in Kronos Bio during the fourth quarter valued at approximately $48,000. Velan Capital Investment Management LP acquired a new stake in Kronos Bio during the fourth quarter valued at approximately $33,000. Squarepoint Ops LLC acquired a new stake in Kronos Bio during the fourth quarter valued at approximately $93,000. Tang Capital Management LLC acquired a new stake in shares of Kronos Bio during the 4th quarter worth approximately $953,000. Finally, Gilead Sciences Inc. acquired a new stake in shares of Kronos Bio during the 4th quarter worth approximately $179,000. 64.09% of the stock is owned by institutional investors and hedge funds.
About Kronos Bio
(
Get Free Report)
Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kronos Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kronos Bio wasn't on the list.
While Kronos Bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
